CLDN18 and gastric cancer: In summary, we investigated the clinicopathological characteristics of CLDN18-ARHGAP26/6 fusion-positive gastric cancers and found that fusion-positive DGCs have strong metastatic ability, a phenotype that is more obvious in younger patients.